VITREO RETINAL PROCEDURES Intravitreal Injection Avastin:

Intravitreal Avastin (also known as IVA) is a procedure that involves injecting the anti-VEGF medicine Avastin into the vitreous cavity of the eye. Macular oedema, or fluid at the back of the eye, is a common complication of diabetes (or retinal vein occlusion or other macular disease such as ARMD).

Avastin is a medication used to treat eye problems that is injected into the eye. The medicine prevents abnormal blood vessels from growing in the rear of the eye. These blood vessels can leak, impairing eyesight and resulting in vision loss. The drug's generic name is Bevacizumab, and its brand name is Avastin.

For a day or two following the injection, you may have intense tearing or slight redness. It's also possible that you'll feel something in your eye, which might be a response to the extremely low-dose iodine solution used to clean your eyes. Artificial tears might assist to relieve any discomfort or dryness.\

Disease Overview:

CRVO (central retinal vein occlusion) is a disorder in which the major vein draining blood from the retina partly or fully shuts. This might result in impaired vision and other eye issues.

Disease Signs and Symptoms:

Due to enlargement of the macula, the central region of the retina, many individuals with CRVO have hazy or distorted vision. Transient visual obscurations are a type of symptom that appears and disappears in certain people.

Disease Causes:

CRVO affects one eye in the majority of individuals. CRVO has no established aetiology, despite the fact that diabetes and high blood pressure are risk factors. What we do know is that CRVO is caused by a blood clot or decreased blood flow in the retina's central retinal vein.

Disease Diagnosis:

CRVO is usually a clinical diagnosis, meaning it is based on medical indications and symptoms recorded by the patient. When a retina expert examines the eye, a pattern of retinal haemorrhages (bleeding) is visible, and a diagnosis is determined.

Disease Treatment:

There is no known effective medical therapy for preventing or treating central retinal vein occlusion (CRVO). To avoid future difficulties, it's critical to identify and address any systemic medical issues. Because the actual pathophysiology of CRVO is unknown, several writers have advocated for various medical treatment approaches, with variable degrees of effectiveness in averting problems and maintaining vision.

One of the most common treatable reasons of reduced visual acuity in people with CRVO is macular edoema. Increased venous pressure, raised levels of VEGF, and dysregulation of various inflammatory mediators all contribute to increased capillary permeability and leakage, although the specific cause causing macular edoema is unknown.To combat distinct aspects of macular edoema, several therapeutic techniques have been tried with significant progress in stabilizing and improving visual acuity